NCT07280494

To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT

An Open-label, Clinical Study of CD7-targeted CAR-T Cells for the Treatment of Measurable Residual Disease of T-lymphoblastic Leukaemia/Lymphoma Post Allogeneic Stem Cell Transplantation

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Peking University People's Hospital · Academic / Other
• Sex: All
• Age: 3 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To observe the efficacy and safety of CD7-targeted chimeric antigen receptor T cells in the treatment of T-lymphoblastic leukaemia/lymphoma with postive measurable residual disease positive post allogeneic stem cell transplantation

Detailed description

This study will explore the efficacy and safety of a natural selection-targeted CD7 CART cell therapy for measurable residual disease after allogeneic hematopoietic stem cell transplantation in T-ALL/LBL. The dose of targeted CD7 CART cells is 2E6 cells/kg, with a single infusion.

Conditions

• CD7+ T-ALL/LBL

Interventions

Type	Name	Description
DRUG	CAR-T Therapy	autologous or donor-derived CD7-targeted CAR-T cells, single injection

Timeline

• Start date: 2025-08-18
• Primary completion: 2026-08-30
• Completion: 2027-12-31
• First posted: 2025-12-12
• Last updated: 2025-12-12

Locations

1 site across 1 country: China